Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Si-Bone (SIBN) Other financing activities (2018 - 2024)

Si-Bone's quarterly Other financing activities came in at $46000.0 in Q4 2024, up 15.0% quarter-over-quarter from $40000.0 in Q1 2023.

Si-Bone has reported Other financing activities for 6 years, with the latest figure at $46000.0 in Q4 2024.

  • For the quarter ending Q4 2024, Other financing activities changed N/A year-over-year to $46000.0; the trailing twelve-month figure through Dec 2024 stood at $46000.0 (up 15.0% YoY), and the FY2024 full-year result was $46000.0, up 15.0% from the prior year.
  • Other financing activities for Q4 2024 stood at $46000.0, up from $40000.0 in the prior quarter.
  • The five-year high for Other financing activities was $400000.0 in Q1 2020, with the low at $40000.0 in Q1 2023.
  • Average Other financing activities over 4 years is $157833.3, with a median of $136000.0 recorded in 2020.
  • Peak annual rise in Other financing activities reached 31.06% in 2021, while the deepest fall reached 31.06% in 2021.
  • Tracing SIBN's Other financing activities over 4 years: stood at $161000.0 in 2020, then slumped by 31.06% to $111000.0 in 2021, then plunged by 63.96% to $40000.0 in 2023, then rose by 15.0% to $46000.0 in 2024.
  • The last three Other financing activities figures came in at $46000.0 (Q4 2024), $40000.0 (Q1 2023), and $111000.0 (Q3 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Si-Bone 611.92 Mn 471.80 Mn 41.94 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 46,000.00
Dec 31, 2024 46,000.00
Mar 31, 2023 40,000.00
Mar 31, 2023 40,000.00
Sep 30, 2021 111,000.00
Sep 30, 2021 111,000.00
Sep 30, 2020 161,000.00
Sep 30, 2020 161,000.00
Jun 30, 2020 189,000.00
Jun 30, 2020 189,000.00
Mar 31, 2020 400,000.00
Mar 31, 2020 400,000.00
Dec 31, 2019 167,000.00
Dec 31, 2019 167,000.00
Dec 31, 2018 1.61 Mn
Dec 31, 2018 1.61 Mn
Sep 30, 2018 288,000.00
Sep 30, 2018 288,000.00